[go: up one dir, main page]

WO2008065500A3 - Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i - Google Patents

Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i Download PDF

Info

Publication number
WO2008065500A3
WO2008065500A3 PCT/IB2007/003604 IB2007003604W WO2008065500A3 WO 2008065500 A3 WO2008065500 A3 WO 2008065500A3 IB 2007003604 W IB2007003604 W IB 2007003604W WO 2008065500 A3 WO2008065500 A3 WO 2008065500A3
Authority
WO
WIPO (PCT)
Prior art keywords
czero
membered
alkylene
heteroaryl
heterocydoalkyi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/003604
Other languages
English (en)
Other versions
WO2008065500A2 (fr
Inventor
Iii John Adams Lowe
Subas Man Sakya
Mark Allen Sanner
Jotham Wadsworth Coe
Stanton Furst Mchardy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2008065500A2 publication Critical patent/WO2008065500A2/fr
Publication of WO2008065500A3 publication Critical patent/WO2008065500A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une série d'hétéroayl amides substitués de formule I, dans laquelle les groupes HET, A, X1 à X4, et R1 à R12 sont définis tels que dans la spécification, qui révèlent une activité en tant qu'inhibiteurs du transport de la glycine. La présente invention concerne également leurs sels pharmaceutiquement acceptables, les compositions pharmaceutiques les contenant, et leur utilisation dans l'amélioration de la cognition et le traitement des symptômes positifs et négatifs de la schizophrénie et d'autres psychoses chez les mammifères, y compris les humains.
PCT/IB2007/003604 2006-11-30 2007-11-19 Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i Ceased WO2008065500A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86789506P 2006-11-30 2006-11-30
US60/867,895 2006-11-30

Publications (2)

Publication Number Publication Date
WO2008065500A2 WO2008065500A2 (fr) 2008-06-05
WO2008065500A3 true WO2008065500A3 (fr) 2008-11-13

Family

ID=39251256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003604 Ceased WO2008065500A2 (fr) 2006-11-30 2007-11-19 Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i

Country Status (1)

Country Link
WO (1) WO2008065500A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002241A1 (es) * 2007-07-31 2009-12-28 Bayer Cropscience Sa Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas.
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
RU2011119217A (ru) * 2008-10-14 2012-11-27 Актелион Фармасьютикалз Лтд Производные фенетиламида и их гетероциклические аналоги
WO2010094666A2 (fr) * 2009-02-17 2010-08-26 Bayer Cropscience Ag N-(phénylcycloalkyl)carboxamide, n-(benzylcycloalkyl)carboxamide et dérivés thiocarboxamides fongicides
WO2010107115A1 (fr) 2009-03-19 2010-09-23 大正製薬株式会社 Inhibiteur de transporteur de glycine
FR2944284A1 (fr) * 2009-04-14 2010-10-15 Sanofi Aventis Derives de n-°7-aza-bicyclo°2.2.1!hept-1-yl)-aryl-methyl! -benzamide, leur preparation et leur application en therapeutique
TW201116516A (en) * 2009-07-15 2011-05-16 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitors
WO2011089576A2 (fr) * 2010-01-25 2011-07-28 Kareus Therapeuttics Sa Nouvelles compositions pour réduire la production de ass 42 et leur utilisation dans le traitement de la maladie d'alzheimer (ad)
CN103003246B (zh) 2010-07-20 2015-11-25 拜尔农科股份公司 作为抗真菌剂的苯并环烯烃
JP2013249257A (ja) * 2010-09-16 2013-12-12 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質
JP2013249258A (ja) * 2010-09-17 2013-12-12 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質
US8729271B2 (en) 2010-09-17 2014-05-20 Taisho Pharmaceutical Co., Ltd Glycine transporter inhibiting substances
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
SI2772484T1 (sl) * 2011-10-18 2017-11-30 Astellas Pharma Inc. Biciklična heterociklična spojina
TW201348243A (zh) * 2012-04-20 2013-12-01 Bayer Cropscience Ag Ｎ－環烷基－ｎ－［（三取代矽烷基苯基）亞甲基］－（硫基）甲醯胺衍生物
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR095264A1 (es) * 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
US9676720B2 (en) * 2013-03-28 2017-06-13 Ube Industries, Ltd. Substituted biaryl compound
CA2960271A1 (fr) * 2014-09-10 2016-03-17 Epizyme, Inc. Composes de cyclohexylamine substitues
MX386752B (es) 2015-09-16 2025-03-19 Metacrine Inc Agonistas del receptor farnesoide x y usos de los mismos.
JP7258763B2 (ja) 2017-03-15 2023-04-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
CA3055990A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du recepteur farnesoide x et leurs utilisations
IL310346A (en) * 2017-10-20 2024-03-01 Univ Vanderbilt Muscarinic acetylcholine M4 receptor antagonists
JP2021503443A (ja) 2017-10-31 2021-02-12 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
WO2019113084A1 (fr) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Formes cristallines et leurs procédés de production
CN112118838A (zh) 2017-12-05 2020-12-22 赛诺维信制药公司 非外消旋混合物及其用途
JP7352294B2 (ja) 2018-02-02 2023-09-28 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
MX2021003110A (es) 2018-09-18 2021-05-13 Metacrine Inc Agonistas del receptor x farnesoide y usos de los mismos.
PH12021553056A1 (en) 2019-06-04 2023-09-11 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
WO2021188695A1 (fr) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations d'un agoniste du récepteur farnésoïde x

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066456A2 (fr) * 2001-02-16 2002-08-29 Allelix Neuroscience, Inc. Inhibiteurs de glyt-1
EP1284257A2 (fr) * 2001-08-16 2003-02-19 Pfizer Products Inc. Ethers aromatiques difluorométhylène et leur utilisation en tant qu'inhibiteurs de transporteur de glycine type 1
WO2005037216A2 (fr) * 2003-10-14 2005-04-28 Pfizer Products Inc. Derives [3.1.0] bicycliques utilises comme inhibiteurs des transporteurs de glycine
WO2006106425A1 (fr) * 2005-04-08 2006-10-12 Pfizer Products Inc. Heteroarylamides bicycliques [3.1.0 ] comme inhibiteurs de transport de la glycine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066456A2 (fr) * 2001-02-16 2002-08-29 Allelix Neuroscience, Inc. Inhibiteurs de glyt-1
EP1284257A2 (fr) * 2001-08-16 2003-02-19 Pfizer Products Inc. Ethers aromatiques difluorométhylène et leur utilisation en tant qu'inhibiteurs de transporteur de glycine type 1
WO2005037216A2 (fr) * 2003-10-14 2005-04-28 Pfizer Products Inc. Derives [3.1.0] bicycliques utilises comme inhibiteurs des transporteurs de glycine
WO2006106425A1 (fr) * 2005-04-08 2006-10-12 Pfizer Products Inc. Heteroarylamides bicycliques [3.1.0 ] comme inhibiteurs de transport de la glycine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERGERON R ET AL: "MODULATION OF N-METHYL-D-ASPARTATE RECEPTOR FUNCTION BY GLYCINE TRANSPORT", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 95, December 1998 (1998-12-01), pages 15730 - 15734, XP002305700, ISSN: 0027-8424 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US12357639B2 (en) 2017-09-22 2025-07-15 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation

Also Published As

Publication number Publication date
WO2008065500A2 (fr) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2008065500A3 (fr) Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
UA88518C2 (ru) Бицикло[3,1,0]гетероариламиды как ингибиторы транспорта глицина типа i
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
MX2007004699A (es) Derivados de indol y bencimidazol.
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
NO20092476L (no) Antibakterielle polycykliske ureaforbindelser
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
MY139446A (en) Novel quinoline derivatives
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
MY147780A (en) Carboxamide compounds and their use as calpain inhibitors
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
UA86037C2 (ru) Бициклические [3.1.0] производные, как ингибиторы переносчика глицина
GB0206860D0 (en) Compounds
NO20074703L (no) Antibakterielle piperidinderivater
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
MY151986A (en) Adamantyl diamide derivatives and uses of same
WO2007044085A3 (fr) Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
HRP20120310T1 (hr) Derivati benzazepina korisni kao antagonisti vazopresina
GB0413087D0 (en) Therapeutic compounds
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
NO20085317L (no) Imidazoazepinonforbindelser
NO20071321L (no) Anti-inflammatoriske midler
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
TW200626158A (en) Naphthaline derivatives
WO2007111983A3 (fr) Nouvelles combinaisons thérapeutiques pour le traitement ou la prévention de troubles psychotiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07825717

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07825717

Country of ref document: EP

Kind code of ref document: A2